Normal view

Received — 10 September 2026 ⏭

Molecular Therapy
In vivo engineering of T cells with a synthetic cytokine receptor enables selective enrichment and expansion of anti-CD22 CAR T cells Travis J. Friesen · Alyssa Sheih · Nikole Perdue · Nolan G. Ericson · Dillon Jarrell · Ashley M. Yingst · Christopher J. Nicolai · Timothy Gervascio · Seungjin Shin · Jessica Freeman · Laurie O. Beitz · Samantha D. O’Hara · Alessandra M. Sullivan · Alissa H. Brandes · Ryan P. Larson · Jeffrey J. Teoh
In preclinical studies, UB-VV400, an off-the-shelf, investigational lentiviral drug product, generates fully human anti-CD22 CAR T cells in vivo without the need for lymphodepletion. Activation of the synthetic rapamycin-activated cytokine receptor drives selective CAR T cell expansion and enrichment, resulting in complete tumor clearance and B cell depletion.
10 August 2026 at 08:00

In vivo engineering of T cells with a synthetic cytokine receptor enables selective enrichment and expansion of anti-CD22 CAR T cells

By: Travis J. Friesen · Alyssa Sheih · Nikole Perdue · Nolan G. Ericson · Dillon Jarrell · Ashley M. Yingst · Christopher J. Nicolai · Timothy Gervascio · Seungjin Shin · Jessica Freeman · Laurie O. Beitz · Samantha D. O’Hara · Alessandra M. Sullivan · Alissa H. Brandes · Ryan P. Larson · Jeffrey J. Teoh

10 August 2026 at 08:00

In preclinical studies, UB-VV400, an off-the-shelf, investigational lentiviral drug product, generates fully human anti-CD22 CAR T cells in vivo without the need for lymphodepletion. Activation of the synthetic rapamycin-activated cytokine receptor drives selective CAR T cell expansion and enrichment, resulting in complete tumor clearance and B cell depletion.